-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although cisplatin-based adjuvant chemotherapy is the standard treatment for stage II and stage III non-small cell lung cancer ( NSCLC ) that are completely resected by surgery , the survival prognosis of patients is not satisfactory
NSCLC
This study (IMPACT) aims to investigate the efficacy of gefitinib in adjuvant treatment of non-small cell lung cancer patients with EGFR mutations
This is an open-label, randomized phase 3 trial that recruits patients with stage II-III non-small cell lung cancer who have been completely resected with EGFR mutation (exon 19 deletion or L858R mutation) and randomly divided into two groups.
Disease-free survival of the two treatment groups
From September 2011 to 2015, a total of 234 patients were recruited and randomly divided into two groups
The median DFS of the gefitinib group and the cisplatin+vinorelbine group were 35.
In summary, although adjuvant gefitinib therapy seems to prevent early recurrence of non-small cell lung cancer, it does not prolong disease-free survival or overall survival
Gefitinib adjuvant treatment of early recurrence prevented appears NSCLC, but it does not prolong disease-free survival or overall survival gefitinib adjuvant treatment of early recurrence prevented appears NSCLC, but it does not prolong disease Survival period or overall survival period
Original source:
Original source:Tada Hirohito, Mitsudomi Tetsuya, Misumi Toshihiro et al.
EGFRRandomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With Mutation (IMPACT)
Leave a message here
